Literature DB >> 17032859

Dynamic CT perfusion imaging with acetazolamide challenge for evaluation of patients with unilateral cerebrovascular steno-occlusive disease.

A Chen1, M-H Shyr, T-Y Chen, H-Y Lai, C-C Lin, P-S Yen.   

Abstract

BACKGROUND AND
PURPOSE: Perfusion CT (PCT) has the ability to measure quantitative values and produce maps of cerebral blood flow (CBF), cerebral blood volume (CBV), and mean transit time (MTT). We assessed cerebral hemodynamics by using these parameters and acetazolamide challenge in patients with cerebrovascular steno-occlusive disease.
METHODS: Fifteen patients underwent PCT with acetazolamide challenge. Comparison of mean CBF, CBV, and MTT was determined between hemispheres and before and after acetazolamide challenge. Hemispheric ratio and percent change due to acetazolamide administration were also calculated. Absolute values and percent changes 2 SDs outside the mean from the nonstenotic hemispheres were defined as abnormal.
RESULTS: Significant decreases in CBF (-25.1%, P = .003) and significant increases in MTT (47.1%, P < .001) were found in stenotic hemispheres. After acetazolamide challenge, significant changes in CBF (-39.5%, P < .001) and MTT (92.9%, P < .001) were also seen. The acetazolamide test significantly decreased CBF hemispheric ratio (-20.3%, P < .001) and increased MTT hemispheric ratio (30.8%, P = .002), making both maps more asymmetric. Significance in CBF and MTT percent changes (P < .001 and P = .005, respectively) was found between hemispheres. When CBF percent changes were assumed to represent the true determinant of hemodynamic impairment, normal ranges of baseline MTT value and MTT percent changes demonstrated sensitivities of 66.7% and 100% and specificities of 58.3% and 75%, respectively, for detecting patients with hemodynamic impairment.
CONCLUSION: Parameters obtained from PCT with acetazolamide are promising for the evaluation of cerebral hemodynamics in patients with cerebrovascular steno-occlusive disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17032859      PMCID: PMC7977914     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  24 in total

1.  Correlation of regional cerebral blood flow measured by stable xenon CT and perfusion MRI.

Authors:  T Hagen; K Bartylla; U Piepgras
Journal:  J Comput Assist Tomogr       Date:  1999 Mar-Apr       Impact factor: 1.826

2.  Transient neurologic deficit after acetazolamide challenge for computed tomography perfusion imaging.

Authors:  Vaishali Choksi; Marion Hughes; Linda Selwa; Ellen Hoeffner
Journal:  J Comput Assist Tomogr       Date:  2005 Mar-Apr       Impact factor: 1.826

Review 3.  Comparative overview of brain perfusion imaging techniques.

Authors:  Max Wintermark; Musa Sesay; Emmanuel Barbier; Katalin Borbély; William P Dillon; James D Eastwood; Thomas C Glenn; Cécile B Grandin; Salvador Pedraza; Jean-François Soustiel; Tadashi Nariai; Greg Zaharchuk; Jean-Marie Caillé; Vincent Dousset; Howard Yonas
Journal:  Stroke       Date:  2005-08-11       Impact factor: 7.914

4.  Dynamic CT measurement of cerebral blood flow: a validation study.

Authors:  A Cenic; D G Nabavi; R A Craen; A W Gelb; T Y Lee
Journal:  AJNR Am J Neuroradiol       Date:  1999-01       Impact factor: 3.825

5.  CT assessment of cerebral perfusion: experimental validation and initial clinical experience.

Authors:  D G Nabavi; A Cenic; R A Craen; A W Gelb; J D Bennett; R Kozak; T Y Lee
Journal:  Radiology       Date:  1999-10       Impact factor: 11.105

6.  A CT method to measure hemodynamics in brain tumors: validation and application of cerebral blood flow maps.

Authors:  A Cenic; D G Nabavi; R A Craen; A W Gelb; T Y Lee
Journal:  AJNR Am J Neuroradiol       Date:  2000-03       Impact factor: 3.825

7.  Variability of cerebral blood volume and oxygen extraction: stages of cerebral haemodynamic impairment revisited.

Authors:  Colin P Derdeyn; Tom O Videen; Kent D Yundt; Susanne M Fritsch; David A Carpenter; Robert L Grubb; William J Powers
Journal:  Brain       Date:  2002-03       Impact factor: 13.501

8.  Acetazolamide test in detecting reduced cerebral perfusion reserve and predicting long-term prognosis in patients with internal carotid artery occlusion.

Authors:  S Kuroda; H Kamiyama; H Abe; K Houkin; M Isobe; K Mitsumori
Journal:  Neurosurgery       Date:  1993-06       Impact factor: 4.654

9.  Reversible pontine ischemia caused by acetazolamide challenge.

Authors:  M Komiyama; M Nishikawa; T Yasui; H Sakamoto
Journal:  AJNR Am J Neuroradiol       Date:  1997-10       Impact factor: 3.825

10.  Evaluation of the cerebral vasodilatory capacity by the acetazolamide test before EC-IC bypass surgery in patients with occlusion of the internal carotid artery.

Authors:  S Vorstrup; B Brun; N A Lassen
Journal:  Stroke       Date:  1986 Nov-Dec       Impact factor: 7.914

View more
  18 in total

1.  Which CT perfusion parameter best reflects cerebrovascular reserve?: correlation of acetazolamide-challenged CT perfusion with single-photon emission CT in Moyamoya patients.

Authors:  N-J Rim; H S Kim; Y S Shin; S Y Kim
Journal:  AJNR Am J Neuroradiol       Date:  2008-07-10       Impact factor: 3.825

2.  Vasodilatory capacity of the cerebral vasculature in patients with carotid artery stenosis.

Authors:  R P H Bokkers; F J Wessels; H B van der Worp; J J M Zwanenburg; W P Th M Mali; J Hendrikse
Journal:  AJNR Am J Neuroradiol       Date:  2011-03-10       Impact factor: 3.825

3.  Patient selection for revascularization procedures in adult Moyamoya disease based on dynamic perfusion computerized tomography with acetazolamide challenge (PCTA).

Authors:  Norberto Andaluz; Ondrej Choutka; Achala Vagal; Rhonda Strunk; Mario Zuccarello
Journal:  Neurosurg Rev       Date:  2010-02-06       Impact factor: 3.042

4.  A comparative study of perfusion CT and 99m Tc-HMPAO SPECT measurement to assess cerebrovascular reserve capacity in patients with internal carotid artery occlusion.

Authors:  Sven O Eicker; B Turowski; H-J Heiroth; H-J Steiger; D Hänggi
Journal:  Eur J Med Res       Date:  2011-11-10       Impact factor: 2.175

5.  Optimal timing for measuring cerebral blood flow after acetazolamide administration to detect preexisting cerebral hemodynamics and metabolism in patients with bilateral major cerebral artery steno-occlusive diseases: 15O positron emission tomography studies.

Authors:  Masakazu Kobayashi; Suguru Igarashi; Tatsuhiko Takahashi; Shunrou Fujiwara; Kohei Chida; Kazunori Terasaki; Yoshitaka Kubo; Kuniaki Ogasawara
Journal:  Am J Nucl Med Mol Imaging       Date:  2021-12-15

6.  Tracer delay-insensitive algorithm can improve reliability of CT perfusion imaging for cerebrovascular steno-occlusive disease: comparison with quantitative single-photon emission CT.

Authors:  M Sasaki; K Kudo; K Ogasawara; S Fujiwara
Journal:  AJNR Am J Neuroradiol       Date:  2008-09-03       Impact factor: 3.825

7.  Quantitative cerebrovascular reserve measured by acetazolamide-challenged dynamic CT perfusion in ischemic adult Moyamoya disease: initial experience with angiographic correlation.

Authors:  K H Kang; H S Kim; S Y Kim
Journal:  AJNR Am J Neuroradiol       Date:  2008-05-22       Impact factor: 3.825

8.  Prediction of cerebral hyperperfusion syndrome after carotid artery stenting by CT perfusion imaging with acetazolamide challenge.

Authors:  Tomohide Yoshie; Toshihiro Ueda; Tatsuro Takada; Shinji Nogoshi; Takayuki Fukano; Yasuhiro Hasegawa
Journal:  Neuroradiology       Date:  2015-12-02       Impact factor: 2.804

Review 9.  Basal and Acetazolamide Brain Perfusion SPECT in Internal Carotid Artery Stenosis.

Authors:  Teck Huat Wong; Qaid Ahmed Shagera; Hyun Gee Ryoo; Seunggyun Ha; Dong Soo Lee
Journal:  Nucl Med Mol Imaging       Date:  2020-01-08

10.  Vascular space occupancy (VASO) cerebral blood volume-weighted MRI identifies hemodynamic impairment in patients with carotid artery disease.

Authors:  Manus J Donahue; Peter Jan van Laar; Peter C M van Zijl; Robert D Stevens; Jeroen Hendrikse
Journal:  J Magn Reson Imaging       Date:  2009-03       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.